ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD) - LARVOL DELTA

MMRVNS 20-002: A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age (clinicaltrials.gov) - P3 | N=1860 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age (clinicaltrials.gov) - P3 | N=1209 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Comparative analysis of the impact of chickenpox and herpes zoster vaccination in Belgium under two different exogenous boosting mechanisms. (PubMed, PLoS One) - "Both models predicted that universal CP vaccination would result in significant reductions in the burden of CP disease, however, the HZ disease burden impact varied significantly depending on the assumed boosting mechanism. Hence, the choice of modeled exogenous boosting mechanism leads to different optimal vaccination strategies. Ascertaining the relative accuracy of these structural model choices will require continued research on the mechanism of VZV boosting."

Clinical • Journal • Herpes Zoster • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age (clinicaltrials.gov) - P3 | N=1209 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD®) reported to the vaccine adverse event reporting system (VAERS), 2015-2025. (PubMed, Virol J) - "This real-world pharmacovigilance analysis confirms the expected safety profile of PROQUAD while revealing additional adverse event signals that merit further clinical investigation and potential regulatory attention. Continued monitoring is essential to inform vaccine safety practices, particularly in pediatric populations with heightened susceptibility."

Adverse events • Journal • CNS Disorders • Dermatology • Epilepsy • Infectious Disease • Influenza • Measles • Mumps • Pediatrics • Respiratory Diseases • Rubella • Varicella Zoster

Effects of Thermal and Antibiotic Treatments on the Viral Accumulation of FcMV1 in Fusarium circinatum Isolates. (PubMed, J Fungi (Basel)) - "For this purpose, three replicates of each isolate were exposed to thermal treatment (38 °C) and antibiotic treatment (ribavirin, cycloheximide, kanamycin, and rifampicin mixed with cAMP)(cyclic adenosine monophosphate) for five successive passages. The isolate Fc179 was found to be more prone to antibiotic treatment than the other two isolates (001 and Va221). This study demonstrated the possibility of using some isolates of F. circinatum for fine-tuning cures for mitovirus, in order to create virus-free strains for biological control in the future."

Journal • Infectious Disease

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (clinicaltrials.gov) - P2 | N=801 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Cystine-knot peptide inhibitors of HTRA1 bind to a cryptic pocket within the active site region. (PubMed, Nat Commun) - "The opening and closing of this cryptic pocket is controlled by the gatekeeper residue V221, and its movement is facilitated by the absence of a constraining disulfide bond that is typically present in trypsin fold serine proteases, thereby explaining the remarkable selectivity of the CKPs. Our findings reveal an intriguing mechanism for modulating the activity of HTRA1, and highlight the utility of CKP-based phage display platforms in uncovering potent and selective inhibitors against challenging therapeutic targets."

Journal • Age-related Macular Degeneration • Immunology • Macular Degeneration • Ophthalmology • Osteoarthritis • Pain • Retinal Disorders • Rheumatology • HTRA1

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (clinicaltrials.gov) - P2 | N=801 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2024 ➔ Oct 2024 | Trial primary completion date: Jan 2024 ➔ Jun 2024

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster